0

Retinitis Pigmentosa - A Pipeline Analysis Report

  • Published: Jul 2018
  • Pages: 80
  • SKU: IRTNTR23300
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for retinitis pigmentosa including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, and target.

Overview of the drug development pipeline for retinitis pigmentosa

Retinitis pigmentosa is a genetic disorder that results in vision loss. It is known to progress over a period and results in complete blindness. Retinitis pigmentosa is caused by mutations in one of over 100 types of genes. The breakdown and loss of cells in the retina are also known to cause retinitis pigmentosa. Patients with this disease generally inherit the disease from their parents. The onset is often in childhood. However, in some cases, the disease does not begin until adulthood. The type and speed of vision loss caused by retinitis pigmentosa differ from person to person and factors, such as the form of the condition. Retinitis pigmentosa can further broadly be classified into three categories namely nonsyndromic, syndromic, and secondary. Nonsyndromic is when the disease occurs alone and does not affect any other sensory organs. While syndromic occurs when retinitis pigmentosa occurs with other neurosensory disorders or developmental abnormalities. Secondary occurs because of the other systemic diseases. The prevalence of the disease is higher in children and young adults compared with the older population. It progresses faster between the age of 20 and 60 years. According to NLM, a part of NIH, retinitis pigmentosa is estimated to affect 100 in every 350,000 to 400,000 people in the US and Europe. The global prevalence is 100 in every 300,000 to 700,000 people. As a result, the rising incidences of the disease are further expected to promote the drug development for retinitis pigmentosa in the forthcoming years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for retinitis pigmentosa. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of retinitis pigmentosa. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

  • Acucela
  • AGTC
  • Astellas Pharma
  • Bayer
  • Novartis

Therapeutic assessment of the drug development pipeline for retinitis pigmentosa by route of administration

  • Subretinal
  • Intravitreal
  • Implant
  • Intraocular
  • Topical

The subretinal route of administration (ROA) involves the application of the drug directly between the photoreceptors and the retinal pigment epithelium in the eye, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for retinitis pigmentosa by therapy

  • Monotherapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for retinitis pigmentosa are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

  • What are the drug molecules in the various development stages for retinitis pigmentosa?
  • What are the companies that are currently involved in the development of drug molecules for retinitis pigmentosa?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule

 

Technavio also offers customization on reports based on specific client requirement.

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>